We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

MICROBIOLOGICS INC.

Microbiologics is a biological products and services provider that partners with healthcare and life science laborato... read more Featured Products: More products

Download Mobile App





Microbiologics Introduces SARS-CoV-2 Synthetic RNA for COVID-19 Research

By LabMedica International staff writers
Posted on 18 Mar 2020
Microbiologics, Inc. More...
(Saint Cloud, MN, USA) has prepared synthetic RNA for SARS-CoV-2 to assist in the efforts to monitor the spread of COVID-19.

Microbiologics, a biological products and services provider, partners with healthcare and life science laboratories, manufacturers and suppliers across the world to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology.

The SARS-CoV-2 material is a 1044 nucleotide RNA specific for the SARS-CoV-2 N (nucleocapsid) gene. It contains all three markers (N1, N2 and N3) detected by the CDC Real-Time RT PCR Panel for Detection of 2019 Novel Coronavirus. The RNA material assists in the development of diagnostic assays and the evaluation of the performance of nucleic acid tests for determination of the presence of SARS-COV-2.

The SARS-CoV-2 RNA is available in two different concentrations: 1 x 106 and 1 x 109 genome copies per tube. An IVD version of the product will be added to the Helix EliteTM line from Microbiologics and will be available in the coming weeks.

“We are engaged with our partners and researchers to offer Microbiologics’ virology and molecular biology capabilities to accelerate diagnostics and therapeutic research,” said Brian Beck, Microbiologics’ VP of R&D. “This new RNA material from Microbiologics mimics the viral nucleic acid and provides the exact targets specified by the CDC.”

“In order to effectively respond to the COVID-19 outbreak, scientists need to have confidence in their diagnostic tools to provide rapid, accurate results,” added Beck. “This SARS-CoV-2 material is a critical step forward in our global response against this new strain of coronavirus.”

Related Links:
Microbiologics, Inc.


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.